American Society of Clinical Oncology (ASCO)
2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations
SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that two latest clinical study results of its Nectin-4-targeting ADC 9MW2821 in combination with toripalimab for urothelial carcinoma wil...
2026 ASCO Preview | Alphamab Oncology to Present Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast Cancer
SUZHOU, China, April 23, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the results from a Phase I clinical study (JSKN016-101, NCT06592417) of its first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC) JSKN016, for the treatment of HER2-negative lo...
2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation
SUZHOU, China, April 22, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the significant results from the Phase III clinical study (KN026-004) of HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with...
Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting
CHENGDU, China, April 22, 2026 /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 29 to June 2. In this meeting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) will present results from three clinical studies, includi...
Innovent to Present New Clinical Data of IBI363（PD-1/IL-2α-biased bispecific fusion protein） at the 2026 ASCO Annual Meeting
SAN FRANCISCO and SUZHOU, China, April 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmun...
ViGenCell's VT-EBV-N Selected for Oral Presentation at ASCO 2026
Phase 2 study of EBV-specific T cell therapy to be presented at a leading oncology meeting SEOUL, South Korea, April 21, 2026 /PRNewswire/ -- ViGenCell Inc. (KOSDAQ: 308080), a clinical-stage biotechnology company based in South Korea focused on advanced cell therapies, today announced that resu...
Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity
* Bio-Techne introduces a streamlined brand architecture that organizes its technologies into three focused portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™. * The new brand structure reflects the scientific journey, connecting early discoveries to translational...
Mexican company Farmacias Similares brings Dr. Simi to Tokyo in Japan debut
A pop-up store is being opened by Farmacias Similares in Shibuya, which is in the heart of Tokyo. TOKYO, April 15, 2026 /PRNewswire/ -- Dressed as a samurai and with his trademark energetic attitude, Dr. Simi—the face of Farmacias Similares— greets curious visitors stopping by the company's pop-...
Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies
SHANGHAI, April 9, 2026 /PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies,today announced the cumulative closing of a pre-IPO financing round in excess of $110 million. The round was co-led...
Nancy L. Lewis, MD, MBS, FACP, Named New Chief Scientific Officer for National Comprehensive Cancer Network (NCCN)
Accomplished medical research leader will oversee NCCN programs to advance clinical trials and improve the quality, effectiveness, and accessibility of cancer care. PLYMOUTH MEETING, Pa., April 9, 2026 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leadi...
NCCN 2026 Annual Conference Prepares Cancer Care Providers Worldwide for Healing the Whole Patient
Pressing issues in oncology, including rising cancer incidences in younger people, plus global opportunities for improving outcomes, were presented alongside cutting-edge research and clinical guidelines updates, during yearly event hosted by the National Comprehensive Cancer Network. ORLANDO, F...
Guiyang hosts 20th Guizhou Tourism Industry Development Conference
GUIYANG, China, March 31, 2026 /PRNewswire/ -- A news report from China Daily:
Co-PSMA data published in the European Urology journal
SYDNEY, March 31, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the results fro...
3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone
SHANGHAI, March 31, 2026 /PRNewswire/ -- 3SBio Inc. (01530.HK
CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0
Rapid Advancement Across Core R&D Pipeline * The global, multicenter Phase I/II clinical trial of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) is actively enrolling patients in Australia and China, and the Phase II IND application has been approved in the US. CS2009 demonstrates an excellent...
CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
Key Highlights: * Excellent Safety Profile: As of mid-March 2026, 113 heavily pretreated patients with solid tumors have been enrolled in the Phase I trial of CS2009, with a median follow-up of approximately 6 months. The more mature data continue to show a favorable safety profile, with23% i...
Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights
SUZHOU, China, March 26, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2025 and highlighted recent business progress. Key Highlights * KN026 (Anbenitamab) achieved robust PFS and OS benefits in second- or third-lin...
Wolfbox® Debuts at 60th Easter Jeep Safari With Off-Road Visibility Tech Showcase
Also a sponsor for three iconic Moab trail runs at America's premier off-road
event, Wolfbox will host an interactive booth to spotlight the brand's off-road
visibility technology and trail-ready gear.
MOAB, Utah, March 25, 2026 /PRNewswire/ -- Wolfbox
DualityBio (9606.HK) Announces 2025 Annual Results
HONG KONG, March 24, 2026 /PRNewswire/ -- Duality Biotherapeutics, Inc. (Hong Kong Stock Exchange Code: 09606.HK, hereinafter referred to as "DualityBio" or the "Company"), a leading global clinical-stage innovative biopharmaceutical company, today announced its first annual results since listing...
KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF
* Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximately RMB1478.78 million, representing a year-on-year increase. * R&D Expenses was approximately RMB1319.68 million. * Loss for the period was RMB381.97 million, adjusted annual loss[1] was approxim...
Week's Top Stories
Most Reposted
Agoda Establishes Strategic Partnership with Taipei City Government, Promoting International Tourism Development
[Picked up by 314 media titles]
2026-04-16 17:15
Singapore imagines new ways of living at Milan Design Week with the opening of Prototype Island
[Picked up by 302 media titles]
2026-04-21 10:28
Blaize and Winmate Announce Strategic Collaboration to Advance Sovereign Edge AI Capabilities for Defense and Critical Infrastructure
[Picked up by 298 media titles]
2026-04-16 18:00
One Bangkok Hosted "Sunsational Songkran Festival 2026"
[Picked up by 292 media titles]
2026-04-16 15:34
Blaize and Datacomm Sign Technology Alliance MOU to Explore AI Inference Solutions Across Indonesia
[Picked up by 292 media titles]
2026-04-21 18:00
Most Read
Shanghai Electric Reports Strong 2025 Performance, New Orders Hit Record High
/C O R R E C T I O N -- JinkoSolar Holding Co., Ltd./
NYSE Content Update: Defense Tech Company AEVEX to Make Its Public Debut
vivo Unveils X300 FE: Bringing ZEISS Super Telephoto Camera to a Compact Design
